NVMI Stock Analysis: Nova | NASDAQ
Semiconductor Equipment & Materials | NASDAQ, USA | Market Cap: 11.797m USD | 12M Return: 48.3% | IL0010845571 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 166M
EPS Trend: 98.1%
Qual. Beats: 2
Rev. Trend: 97.9%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nova Ltd. (NASDAQ: NVMI) is an Israel-based provider of process control and metrology systems used in semiconductor manufacturing. The company designs, develops, produces, and sells equipment that performs dimensional, film, and materials/chemical metrology measurements across key wafer fabrication steps, including lithography, etch, chemical mechanical planarization (CMP), deposition, electrochemical plating, and advanced packaging. Nova sells its systems globally, with material exposure to Taiwan, the United States, China, and Korea, and serves the logic, foundry, memory, and packaging segments, as well as process equipment manufacturers. The company was incorporated in 1993, is headquartered in Rehovot, Israel, and was renamed from Nova Measuring Instruments Ltd. to Nova Ltd. in July 2021.
Within the broader semiconductor value chain, Nova operates in the Semiconductor Materials & Equipment sub-industry, supplying metrology tools that help chipmakers monitor and control critical process parameters as device geometries shrink. Process control metrology is a relatively concentrated sub-segment of the wafer fab equipment (WFE) market, with demand closely tied to fab capital spending and the increasing complexity of advanced nodes and 3D/advanced packaging architectures.
- Advanced packaging metrology orders surge on AI chip demand
- Wafer fab equipment spending recovery lifts process control revenue
- China and Taiwan revenue concentration exposes to geopolitical risks
| Net Income: 270.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -5.85 > 1.0 |
| NWC/Revenue: 55.07% < 20% (prev 68.20%; Δ -13.12% < -1%) |
| CFO/TA 0.09 > 3% & CFO 212.4m > Net Income 270.4m |
| Net Debt (-147.6m) to EBITDA (330.2m): -0.45 < 3 |
| Current Ratio: 1.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (34.5m) vs 12m ago 7.48% < -2% |
| Gross Margin: 57.12% > 18% (prev 57.10%; Δ 0.02% > 0.5%) |
| Asset Turnover: 46.61% > 50% (prev 52.63%; Δ -6.02% > 0%) |
| Interest Coverage Ratio: 132.3 > 6 (EBIT TTM 306.4m / Interest Expense TTM 2.32m) |
| A: 0.21 (Total Current Assets 1.45b - Total Current Liabilities 936.6m) / Total Assets 2.49b |
| B: 0.42 (Retained Earnings 1.06b / Total Assets 2.49b) |
| C: 0.15 (EBIT TTM 306.4m / Avg Total Assets 2.01b) |
| D: 1.43 (Book Value of Equity 1.47b / Total Liabilities 1.02b) |
| Altman-Z'' = 5.27 = AAA |
| DSRI: 1.31 (Receivables 210.3m/138.4m, Revenue 937.5m/807.1m) |
| GMI: 1.00 (GM 57.10% / 57.12%) |
| AQI: 1.11 (AQ_t 0.35 / AQ_t-1 0.32) |
| SGI: 1.16 (Revenue 937.5m / 807.1m) |
| TATA: 0.02 (NI 270.4m - CFO 212.4m) / TA 2.49b) |
| Beneish M = -2.59 (Cap -4..+1) = A |
As of September 06, 2026, the stock is trading at USD 372.10 with a total of 700,409 shares traded. Over the past week, the price has changed by +6.60%, over one month by -10.01%, over three months by -28.50% and over the past year by +48.28%.
Current recommended Stop Loss: 344.90 (which is 7.3% or 1.4 ATR below the current price).
Nova has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy NVMI.
- StrongBuy: 5
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 532 | 43% |
P/E Trailing = 46.1337
P/E Forward = 34.7222
P/S = 12.5839
P/B = 7.969
P/EG = 1.4554
Revenue TTM = 937.5m USD
EBIT TTM = 306.4m USD
EBITDA TTM = 330.2m USD
Long Term Debt = 731.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 743.7m USD (from shortTermDebt, last quarter)
Debt = 873.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 69.9m
Net Debt = -147.6m USD (calculated: Debt 873.4m - CCE 1.02b)
Enterprise Value = 11.6b USD (11.8b + Debt 873.4m - CCE 1.02b)
Interest Coverage Ratio = 132.3 (Ebit TTM 306.4m / Interest Expense TTM 2.32m)
EV/FCF = 61.39x (Enterprise Value 11.6b / FCF TTM 189.8m)
FCF Yield = 1.63% (FCF TTM 189.8m / Enterprise Value 11.6b)
FCF Margin = 20.24% (FCF TTM 189.8m / Revenue TTM 937.5m)
Net Margin = 28.84% (Net Income TTM 270.4m / Revenue TTM 937.5m)
Gross Margin = 57.12% ((Revenue TTM 937.5m - Cost of Revenue TTM 402.0m) / Revenue TTM)
Gross Margin QoQ = 56.54% (prev 57.66%)
Tobins Q-Ratio = 4.68 (Enterprise Value 11.6b / Total Assets 2.49b)
Interest Expense / Debt = 0.27% (Interest Expense 2.32m / Debt 873.4m)
Taxrate = 15.32% (48.9m / 319.3m)
NOPAT = 259.4m (EBIT 306.4m * (1 - 15.32%))
Current Ratio = 1.55 (Total Current Assets 1.45b / Total Current Liabilities 936.6m)
Debt / Equity = 0.60 (Debt 873.4m / totalStockholderEquity, last quarter 1.47b)
Debt / EBITDA = -0.45 (Net Debt -147.6m / EBITDA 330.2m)
Debt / FCF = -0.78 (Net Debt -147.6m / FCF TTM 189.8m)
Total Stockholder Equity = 1.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.44% (Net Income 270.4m / Total Assets 2.49b)
RoE = 20.25% (Net Income TTM 270.4m / Total Stockholder Equity 1.34b)
RoCE = 14.82% (EBIT 306.4m / Capital Employed (Equity 1.34b + L.T.Debt 731.7m))
RoIC = 11.53% (NOPAT 259.4m / Invested Capital 2.25b)
WACC = 12.52% (E(11.8b)/V(12.7b) * Re(13.43%) + D(873.4m)/V(12.7b) * Rd(0.27%) * (1-Tc(0.15)))
Discount Rate = 13.43% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 81.72 | Cagr: 3.11%
[DCF] Terminal Value 60.74% ; FCFF base≈196.5m ; Y1≈183.8m ; Y5≈168.8m
[DCF] Fair Price = 54.21 (EV 1.58b - Net Debt -147.6m = Equity 1.72b / Shares 31.8m; r=12.52% [WACC]; 5y FCF grow -8.19% → 2.50% )
EPS Correlation: 98.06 | EPS CAGR: 29.79% | SUE: 1.46 | # QB: 2
Revenue Correlation: 97.90 | Revenue CAGR: 28.23% | SUE: 1.51 | # QB: 2
EPS current Quarter (2026-09-30): EPS=2.77 | Chg30d=+3.56% | Revisions=+38% | Analysts=8
EPS current Year (2026-12-31): EPS=10.67 | Chg30d=+2.05% | Revisions=+44% | GrowthEPS=+23.8% | GrowthRev=+22.4%
EPS next Year (2027-12-31): EPS=13.66 | Chg30d=+5.36% | Revisions=+50% | GrowthEPS=+28.0% | GrowthRev=+26.2%
[Analyst] Revisions Ratio: +57% (up=15, down=3)